111 related articles for article (PubMed ID: 24571893)
21. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.
Kawakami T; Machida N; Yasui H; Kawahira M; Kawai S; Kito Y; Yoshida Y; Hamauchi S; Tsushima T; Todaka A; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y
Cancer Chemother Pharmacol; 2016 Oct; 78(4):809-14. PubMed ID: 27566700
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Bamias A; Papamichael D; Syrigos K; Pavlidis N
J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).
Sakai D; Satoh T; Kurokawa Y; Kudo T; Nishikawa K; Oka Y; Tsujinaka T; Shimokawa T; Doki Y; Furukawa H
Jpn J Clin Oncol; 2013 Aug; 43(8):838-40. PubMed ID: 23852648
[TBL] [Abstract][Full Text] [Related]
27. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.
Takahashi N; Suzuki H; Iwabuchi S; Yamazaki Y; Yanaga K
Hepatogastroenterology; 2005; 52(61):326-8. PubMed ID: 15783061
[TBL] [Abstract][Full Text] [Related]
28. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
30. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
Farhat FS; Kattan J; Ghosn MG
Expert Rev Anticancer Ther; 2010 Apr; 10(4):541-8. PubMed ID: 20397919
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Makiyama A; Arimizu K; Hirano G; Makiyama C; Matsushita Y; Shirakawa T; Ohmura H; Komoda M; Uchino K; Inadomi K; Arita S; Ariyama H; Kusaba H; Shinohara Y; Kuwayama M; Kajitani T; Oda H; Esaki T; Akashi K; Baba E
Gastric Cancer; 2018 May; 21(3):464-472. PubMed ID: 28799048
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
Komaki R; Janjan NA; Ajani JA; Lynch PM; Fairweather JS; Raijman I; Blumenshein GR; Ho L; Pisters PW; Feig BW; Walsh GL; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):34-7. PubMed ID: 11200147
[TBL] [Abstract][Full Text] [Related]
33. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Sym SJ; Hong J; Park J; Cho EK; Lee JH; Park YH; Lee WK; Chung M; Kim HS; Park SH; Shin DB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):481-8. PubMed ID: 23192279
[TBL] [Abstract][Full Text] [Related]
35. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
36. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer.
Xiong BH; Cheng Y; Ma L; Zhang CQ
Cancer Invest; 2014 Jul; 32(6):272-84. PubMed ID: 24800782
[TBL] [Abstract][Full Text] [Related]
37. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Uedo N; Narahara H; Ishihara R; Takiuchi H; Goto M; Fujitani K; Hirao M; Tsujinaka T; Imano M; Furukawa H; Tsukuma H; Taguchi T
Oncology; 2007; 73(1-2):65-71. PubMed ID: 18334851
[TBL] [Abstract][Full Text] [Related]
39. Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Ueda A; Hosokawa A; Ogawa K; Yoshita H; Mihara H; Ando T; Kajiura S; Fujinami H; Nishikawa J; Minemura M; Terada M; Kobayashi T; Horikawa N; Yabushita K; Note M; Sugiyama T
Anticancer Res; 2013 Nov; 33(11):5107-11. PubMed ID: 24222156
[TBL] [Abstract][Full Text] [Related]
40. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
